In this context, the oncogene MYC was predicted to be the highest activation regulator in Class A. Despite some limitations, such as the unknown location of biopsy (given tumor heterogeneity in GBM, tissue origin is needed to obtain more accurate samples), this study demonstrated, for the first time, imaging features that predicted metabolic and mitochondrial dysfunction in GBM and identified the latter as possible driver for very aggressive GBM phenotypes and resistance to therapy. The gene discussed is MYC; the disease is glioblastoma.